Following approval, Medtronic began a Customer Training Phase in March to test the device's real-world use. Those that used the MiniMed 670G remained in a healthy blood glucose range 74% of the time.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the ...

GALWAY, Ireland, June 12, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the ...

A recent Medtronic MiniMed Paradigm and 530G pump recall included 444,374 units in the US and 293,000 patients elsewhere. [9] ...

Insulin Pump Risks and Benefits A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. A Joint Statement of the European Association for the Study of Diabetes ...

In this instance, the partnership will combine Senseonics’ Eversense continuous glucose monitor (CGM), TypeZero’s InControl algorithms, and Roche’s Accu-Chek Insight Insulin Pump.

PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin ...

The insulin infusion pump market is expected to further boom in the future with projections suggesting a jump to $10.31 billion by 2029, riding a CAGR of 10.2%.

The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic’s diabetes ...